Beta Bionics, Inc. - Common Stock (BBNX)

NEW YORK and NEW ORLEANS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX) of a class action securities lawsuit.

Beta Bionics (NASDAQ:BBNX) reported third-quarter net sales of $35.5 million, up about 30% from a year earlier, as new patient starts and recurring revenue from its pharmacy-channel user base supported growth. The company also raised the lower end of its full-year revenue outlook and outlined plans

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

IRVINE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2026 and updated its full year guidance for the year ending December 31, 2026.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Beta Bionics (BBNX) To Contact Him Directly To Discuss Their Options

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

A securities class action alleges Beta Bionics kept a June 2025 FDA Form 483 and more than 18,000 unreported iLet complaints out of public view for months, with the dates of each disclosure tracking a $23.09 per-share collapse in BBNX

PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).

A securities class action alleges Beta Bionics assured shareholders that an FDA Form 483 was a "very benign" reporting technicality, and investor confidence held for months until the agency's Warning Letter became public and BBNX shares declined.

LOS ANGELES, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, announces that it has filed a federal securities class action on behalf of purchasers of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics investors have until November 3, 2026 to seek appointment as lead plaintiff of the purported class in the Beta Bionics class action lawsuit. The complaint in Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999 (C.D Cal.) charges Beta Bionics and certain of the Company’s top executive officers with violations of the Securities Exchange Act of 1934.

San Diego, California--(Newsfile Corp. - October 23, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump ("iLet").

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).

NEW YORK CITY, NY / ACCESS Newswire / October 23, 2026 / Levi & Korsinsky, LLP alerts investors in Beta Bionics, Inc. (NASDAQ:BBNX) of a pending securities class action. Class Period: July 30, 2025 through February 24, 2026. Check if you might be eligible to recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.

NEW ORLEANS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX), if they purchased or otherwise acquired the Company’s common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

LOS ANGELES, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, announces that it has filed a federal securities class action on behalf of purchasers of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics investors have until November 3, 2026 to seek appointment as lead plaintiff of the purported class in the Beta Bionics class action lawsuit. The complaint in Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999 (C.D Cal.) charges Beta Bionics and certain of the Company’s top executive officers with violations of the Securities Exchange Act of 1934.

PHILADELPHIA, Oct. 22, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) investors of the November 3, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.

NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”).

NEW YORK and NEW ORLEANS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX) of a class action securities lawsuit.

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.